Chinese drug sector’s stature grows at major cancer conference

Read the original at South China Morning Post ↗
Cite

Shen, X. (2026, October 28). Chinese drug sector’s stature grows at major cancer conference. South China Morning Post. https://www.scmp.com/business/china-business/article/3372422/chinese-drug-sectors-stature-grows-major-cancer-conference

Dated from the outlet's own feed. Check the original for its byline.

South China Morning Post · collected 2026-10-28 · by Xinmei Shen

Quick Summary

At the European Society for Medical Oncology (ESMO) Congress in Madrid, an increasing number of Chinese pharmaceutical companies like Hansoh Pharmaceutical and Akeso showcased positive results for new cancer treatments. The conference included 29 out of 96 late-breaking abstracts and five out of twelve studies in the prestigious presidential symposium from Chinese firms, highlighting China’s growing influence in biotech research and development.
Written locally by qwen2.5:14b on 2026-10-28, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

At the recent European Society for Medical Oncology (Esmo) Congress in Madrid, Chinese drug makers significantly increased their presence, presenting positive trial results for new cancer treatments. The conference, held from October 23 to 27, featured 96 late-breaking abstracts, with 29 coming from China and five out of the twelve studies selected for the prestigious presidential symposium also originating from Chinese firms. Companies like Hansoh Pharmaceutical and Akeso highlighted their innovative drugs, particularly antibody-drug conjugates (ADCs), which showed promising data across various tumor types, signaling a growing international influence for China’s biotech sector.

Written for “Chinese Drug Sector Grows” on 2026-10-28, grounded in this article and the 0 other(s) covering the same event.

Story

📰 Chinese Drug Sector Grows
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
5
sentences that state something as happening or true
Uncertain
0%
0 of 5 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
64/100
South China Morning Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-28 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

South China Morning Post · 3272 article(s) · 6 correction(s) detected
Running correction rate · 6 correction(s)
2026-10-16
Nobel Peace Prize: the message behind Navi Pillay’s win
2026-10-16
Indonesian governor’s Singapore trip adds fury to forest fire, haze crisis
2026-10-04
Flight to Okinawa diverts back to Hong Kong after suspected landing gear fault
2026-10-04
Tennessee prisons chief resigning after botched execution of Christa Pike
2026-09-29
Indonesian prison chief suspended over secret VIP compound for inmates
2026-09-28
Trump ‘arms offer’ to China jolts Washington into moves to contain the fallout

Who wrote this

Xinmei Shen
10 article(s) here · 0 carrying a prediction
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
2026-09-26 · assertive framing · China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
2026-09-23 · speculative framing · Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
Also by Xinmei Shen
Former HSBC executive launches wealth platform powered by team of AI agents
2026-10-12 · South China Morning Post
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
2026-10-07 · South China Morning Post
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
2026-09-26 · South China Morning Post
US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious
2026-09-24 · South China Morning Post
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 10 articles by Xinmei Shen →

Topics

Akeso China Chinese European Hansoh Pharmaceutical

Subjects

Chinese NORP · 5× Akeso ORG · 1× China GPE · 1× China Post Securities ORG · 1× European NORP · 1× Hansoh Pharmaceutical ORG · 1× Madrid GPE · 1×

Narrative

Hansoh Pharmaceutical, Akeso and others tout positive results as Chinese research accounts for larger percentage of presentations An array of Chinese drug makers showcased positive trial results for new cancer treatments at a major European medical conference, underscoring the expanding international influence of China’s biotech sector.
framing: assertive · carried by 1 article(s) · first seen 2026-10-28
2026-10-28 · South China Morning Post
Chinese drug sector’s stature grows at major cancer conference · assertive framing

Claims (5 extracted, 0 hedged)

Chinese drug sector’s stature grows at major cancer conference asserted
stature → grow → conference
Hansoh Pharmaceutical, Akeso and others tout positive results as Chinese research accounts for larger percentage of presentations An array of Chinese drug makers showcased positive trial results for new cancer treatments at a major European medical conference, underscoring the expanding international influence of China’s biotech sector. asserted
array → tout → sector
Domestic innovative drugs, particularly antibody-drug conjugates (ADCs), delivered impressive data across multiple tumour types at the European Society for Medical Oncology (Esmo) Congress, with some early-stage data further showing the country’s “innovation capabilities”, said analysts from China Post Securities in a note on Monday. asserted
analysts → deliver → Monday
Chinese research accounted for 29 of 96 late-breaking abstracts (LBAs) – summaries of newly available clinical research data – presented at the prominent industry conference, held in Madrid from October 23 to 27. asserted
research → account → 27
Five of the 12 studies selected for the prestigious presidential symposium were also from Chinese firms. asserted
Five → select → firms
💬Give feedback
🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 28 Oct 2026